Signals and signposts: Biomarkers in IPF and PAH at the crossroads of clinical relevance.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

2 citing papers in PubMed.

1. Osteopontin as a Biomarker in Interstitial Lung Diseases.Biomedicines · 2024
   Article
2. Molecular Characterization and Elucidation of Pathways to Identify Novel Therapeutic Targets in Pulmonary Arterial Hypertension.Frontiers in physiology · 2021
   Article

Corrections and comments

• Commented on by
  Biomarkers in idiopathic pulmonary fibrosis: Are we there yet?2020
• Comment on
  Osteopontin lung gene expression is a marker of disease severity in pulmonary arterial hypertension.2019
• Comment on
  Analysis by proteomics reveals unique circulatory proteins in idiopathic pulmonary fibrosis.2019

Authors and funding

2 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as